For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

Brexpiprazole Eases Agitation in People with AD; So Does Being in

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

SLU Researcher Finds Help for Alzheimer's-Associated Agitation

Investigation Questions Drug's Approval for Agitation in AD

Alzheimer's Disease Insight Report: Current Therapies, Drug

New approaches to symptomatic treatments for Alzheimer's disease

First-Ever Drug for Alzheimer's Agitation, Brexpiprazole, Nears

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Drugs Archives - Alzheimer's & Dementia Weekly

Statement on the FDA Approval of Brexpiprazole

Controversy Surrounds Brexpiprazole's FDA Approval, a New

New Alzheimer's Disease Drugs

REXULTI® (brexpiprazole), MDD